September 18, 2017 09:20 AM EDTUpdated 09:39 AM

Avanir vet Keith Katkin takes charge at Urovant; Teva unloads assets while uploading new CEO

Shehla Shakoor

Managing Director

⇨ Roivant Sciences has added another seasoned biotech exec to its stable of CEOs. The umbrella group announced this morning that Keith Katkin, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Avanir vet Keith Katkin takes charge at Urovant; Teva unloads assets while uploading new CEO

Shehla Shakoor

Managing Director

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Novartis won bidding war for kidney drug as Regulus' top three execs expect to make over $100M combined

Updated: Patient dies in Rocket gene therapy trial, which is put on clinical hold by FDA

Lilly to buy non-opioid pain biotech SiteOne for up to $1B

RFK Jr. ends annual Covid vaccine recommendations for kids, pregnant women

Biogen taps City Therapeutics in RNAi deal worth up to $1B

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Avanir vet Kei­th Katkin takes charge at Urovant; Te­va un­loads as­sets while up­load­ing new CEO

Managing Director

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Avanir vet Keith Katkin takes charge at Urovant; Teva unloads assets while uploading new CEO